DOCSLIB.ORG

Monsanto & Genetic Engineering

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monsanto & Genetic Engineering Monsanto & Genetic Engineering: Risks for Investors Report prepared by Innovest Strategic Value Advisors For Greenpeace Uncovering Hidden Value Potential for Strategic Investors April 2003 New York: (212) 421-2000 • London: +44 (0) 20 7743 6162 • Toronto: (905) 707-0876 • Paris: +33 (148) 860369 www.innovestgroup.com Report Prepared by Innovest Strategic Value Advisors Marc Brammer Senior Analyst 646-237-0217 [email protected] Frank Dixon, MBA (Media Contacts) Managing Director 646-237-0220 [email protected] Beth Ambrose Analyst +44-207-073-0475 [email protected] For Greenpeace Lindsay Keenan Genetic Engineering Campaigner + 49 30-3088-9916 [email protected] No part of this report may be reproduced in any manner without the written permission of Innovest Strategic Value Advisors, Inc. The information herein has been obtained from sources which we believe to be reliable, but we do not guarantee its accuracy or completeness. All opinions expressed herein are subject to change without notice. Innovest Strategic Value Advisors, Inc., its affiliated companies, or their respective shareholders, directors, officers and/or employees, may have a position in the securities discussed herein. The securities mentioned in this document may not be eligible for sale in some states or countries, nor suitable for all types of investors; their value and the income they produce may fluctuate and/or be adversely affected by exchange rates. © 2003 Innovest Strategic Value Advisors, Inc. All rights reserved. New York Office: Four Times Square, 3rd Floor, New York, NY 10036 USA (212) 421-2000 Fax (212) 421-9663 Toronto Office: 225 East Beaver Creek Road Suite 300, Richmond Hill Ontario L4B 3P4 CANADA (905) 707-0876 Fax (905) 707-9084 London Office: 4 Royal Mint Court, London, EC3N 4HJ ENGLAND +44 (0)20 7073 0470 Fax: +44 (0)20 7073 0473 Paris Office: 110 Boulevard de Sébastopol 75003 Paris FRANCE +33 (0)1 44 54 04 89 Fax: +33 (0)1 44 54 02 30 Website: www.innovestgroup.com Table of Contents 1. EXECUTIVE SUMMARY .................................................................................................................6 MARKET REJECTION............................................................................................................... 7 Foreign Market Rejection................................................................................................. 7 Domestic Market Rejection..............................................................................................8 ENVIRONMENTAL AND HUMAN HEALTH RISKS..................................................................8 Inevitable Environmental Contamination.......................................................................8 Human Health Risks..........................................................................................................9 Ethical Concerns.............................................................................................................. 10 STRATEGIC RISK.................................................................................................................... 10 ANOTHER BLACK EYE FOR THE FINANCIAL COMMUNITY?............................................... 11 2. MONSANTO STOCK PRICE PROJECTIONS...................................................................................13 3. GE CROP DEVELOPMENT & ADOPTION .................................................................................... 16 4. THE RISKS OF MONSANTO’S GE STRATEGY.............................................................................. 19 MARKETING AND GOALS .................................................................................................... 20 Affects of Roundup Competition ...................................................................................21 Genetically Engineered Wheat ...................................................................................... 22 Catastrophic Failure Risks............................................................................................... 24 5. GE RISKS AND THE IMPLICATIONS FOR SHAREHOLDERS ........................................................29 MARKET RISKS...................................................................................................................... 29 Consumer Rejection and U.S. Public Opinion ............................................................... 29 Food Industry Rejection.................................................................................................. 33 REGULATORY RISKS ............................................................................................................. 36 Regional Regulatory Situation....................................................................................... 37 Labeling...........................................................................................................................38 The Biosafety Protocol.................................................................................................... 39 Politics and Genetically Engineered Foods ................................................................... 41 Insuring Genetically Engineered Crops ......................................................................... 42 ENVIRONMENTAL AND HUMAN HEALTH RISKS................................................................ 43 The Technology............................................................................................................... 43 Human Health Risks........................................................................................................ 43 Environmental Risks........................................................................................................45 RISKS BEYOND GENETIC ENGINEERING.............................................................................. 47 6. ANALYSIS OF THE BENEFITS ......................................................................................................50 Lower Pesticide Use & Increased Yields......................................................................... 52 7. CONCLUSIONS: WHAT IS THE FUTURE FOR MONSANTO?.......................................................54 Table of Figures Figure 1. Wall Street Earnings Estimate for Monsanto ................................................................ 14 Figure 2. Stock Price & Earnings Per Share Estimates .................................................................. 14 Figure 3. Innovest Earnings Estimate (Low Conservative Case)................................................... 14 Figure 4. Potential Financial Fallout from Contamination - the “Starlink” Scenario................ 15 Figure 5. Global Commercialized Transgenic Crop Plantings 2002............................................. 16 Figure 6. Transgenic Crops by Traits ..............................................................................................17 Figure 7. Monsanto Product Pipeline............................................................................................20 Figure 8. Canadian Wheat Board – Assessment of Market Acceptance for GE Wheat (2002) ..................................................................................................................................... 23 Figure 9. Wheat Export Market Rejection by Volume (based on Figure 8 above)....................24 Figure 10. Flow Chart of Market Rejection of GMOs ...................................................................29 Figure 11. Intensity Level of GMO Debate in Five Selected European Countries .......................30 Figure 12. U.S. Polling Data on Genetically Engineered Foods (1997-2001) ................................ 33 Figure 13. List of Food Companies with No GMO Policies ...........................................................34 Figure 14. Examples of Regulatory Barriers to GMO Commercialization .......................................38 Figure 15. Drop in U.S. Approval Ratings World-wide................................................................. 41 Figure 16. Direct Payments to U.S. Farmers and GE Crops Plantings ......................................... 51 This page left intentionally blank 1. EXECUTIVE SUMMARY Innovest Strategic Value Advisors, a financial services firm based in New York, London, Paris and Toronto, analyzed investor risks related to Monsanto’s genetic engineering (GE) strategy. Partly owned by State Street Global Advisors and the Dutch pension fund ABP, Innovest is a leader in analyzing the financial impacts of environmental and social issues. Investors use Innovest’s best-in-class ratings, ranging from AAA to CCC, to minimize risk and maximize return potential. In nearly every industry sector, companies with above average environmental scores, taken as a group, outperformed below average firms by 300 to 3000 basis points per year in the stock market. Monsanto received a CCC EcoValue’21™ rating from Innovest, the lowest environmental rating. This implies the firm has above average risk exposure and less sophisticated management than peers. As a result, it will likely underperform in the stock market over the mid to long-term. Monsanto is the global leader in developing and marketing GE seeds (in 2002, 91% of GE hectares world-wide were planted with Monsanto seeds). The company also makes the world’s largest selling herbicide, Roundup/Glyphosate. Its strategy includes selling GE seeds intended to be used with Roundup (71% of GE seeds planted worldwide in 2002 were designed to
Load more

Recommended publications
  • U.S. V. Bayer AG and Monsanto Company Comment: the Sierra Club
    ATTN: Kathleen S. O'Neill Chief, Transportation, Energy & Agriculture Section Antitrust Division United States Department of Justice 450 5th Street, NW, Suite 800 Washington, DC 20530 Petition in opposition to proposed U.S. v. Bayer AG and Monsanto Company settlement and merger: A merger of agrochemical giants Bayer and Monsanto would create the world's largest seed and pesticide maker. I am afraid this move will reduce competition, raise prices for consumers and farmers, and result in an unacceptable degree of control over the agricultural industry and our food supply. I am very concerned about pollinators and the increased risks to bees, butterflies and birds with the increase of Bayer's neonicotinoids. Both companies produce corn products engineered to imply the use of harmful pesticides they manufacture. The production of corn uses high amounts of nitrogen- based fertilizers and the excess sediment is contaminating our waterways, therefore I am deeply worried about increased corn production from this merger. The heavy nutrient runoff from corn is widely attributed to exacerbating the marine "Dead Zone" in the Gulf of Mexico, in which algal blooms create hypoxic conditions wherein oxygen concentration is in such low levels that marine life suffocates and dies. I urge the Department of Justice to do more prevent the Bayer-Monsanto seed and pesticide platform from growing too strong by stopping this merger. If this merger is allowed, it should require more pesticide and seed divestments in order to protect our agriculture and food supply. This merger is anti-competition, if it is approved it will fail to protect farmers, consumers and the environment by allowing further consolidation of the industrial agriculture sector.
    [Show full text]
  • Recombinant DNA and Elements Utilizing Recombinant DNA Such As Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology
    Fact Sheet Describing Recombinant DNA and Elements Utilizing Recombinant DNA Such as Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology Compiled and/or written by Amy B. Vento and David R. Gillum Office of Environmental Health and Safety University of New Hampshire June 3, 2002 Introduction Recombinant DNA (rDNA) has various definitions, ranging from very simple to strangely complex. The following are three examples of how recombinant DNA is defined: 1. A DNA molecule containing DNA originating from two or more sources. 2. DNA that has been artificially created. It is DNA from two or more sources that is incorporated into a single recombinant molecule. 3. According to the NIH guidelines, recombinant DNA are molecules constructed outside of living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, or molecules that result from their replication. Description of rDNA Recombinant DNA, also known as in vitro recombination, is a technique involved in creating and purifying desired genes. Molecular cloning (i.e. gene cloning) involves creating recombinant DNA and introducing it into a host cell to be replicated. One of the basic strategies of molecular cloning is to move desired genes from a large, complex genome to a small, simple one. The process of in vitro recombination makes it possible to cut different strands of DNA, in vitro (outside the cell), with a restriction enzyme and join the DNA molecules together via complementary base pairing. Techniques Some of the molecular biology techniques utilized during recombinant DNA include: 1.
    [Show full text]
  • The Era of Corporate Consolidation and the End of Competition Bayer-Monsanto, Dow-Dupont, and Chemchina-Syngenta
    Research Brief October 2018 The Era of Corporate Consolidation and the End of Competition Bayer-Monsanto, Dow-DuPont, and ChemChina-Syngenta DISRUPT ECOSYSTEM ACCLERATE MONOPOLY THE EFFECTS OF CORPORATE CONSOLIDATION UNDERMINE FOOD SECURITY HARM SMALL PRODUCERS HAASINSTITUTE.BERKELEY.EDU This publication is published by the Haas Institute for a Fair and Inclusive Society at UC Berkeley This research brief is part of the Haas Institute's Shahidi Project from the Global Justice Program. The Shahidi Project (Shahidi is a Swahili word meaning “witness”) intends to demystify the power structures and capacities of transnational food and agricultural corporations within our food system. To that end, researchers have developed a robust database focusing on ten of the largest food and agricultural corporations in the world. See more at haasinstitute.berkeley.edu/shahidi. About the Authors Copyeditor Support Elsadig Elsheikh is the director Marc Abizeid Special thanks to the Food of the Global Justice program and Farm Communications at the Haas Institute for a Infographics Fund, which provided the seed Fair and Inclusive Society at Samir Gambhir funding for the Shahidi project. the University of California- Berkeley, where he oversees Report Citation Contact the program’s projects and Elsadig Elsheikh and Hossein 460 Stephens Hall research on corporate power, Ayazi. “The Era of Corporate Berkeley, CA 94720-2330 food system, forced migration, Consolidation and The End of Tel 510-642-3326 human rights, Islamophobia, Competition: Bayer-Monsanto, haasinstitute.berkeley.edu structural marginality and Dow-DuPont, and ChemChina- inclusion, and trade and Syngenta.” Haas Institute for development. a Fair and Inclusive Society at the University of California, Hossein Ayazi, PhD, is a Berkeley, CA.
    [Show full text]
  • Genetic Engineering and Sustainable Crop Disease Management: Opportunities for Case-By-Case Decision-Making
    sustainability Review Genetic Engineering and Sustainable Crop Disease Management: Opportunities for Case-by-Case Decision-Making Paul Vincelli Department of Plant Pathology, 207 Plant Science Building, College of Agriculture, Food and Environment, University of Kentucky, Lexington, KY 40546, USA; [email protected] Academic Editor: Sean Clark Received: 22 March 2016; Accepted: 13 May 2016; Published: 20 May 2016 Abstract: Genetic engineering (GE) offers an expanding array of strategies for enhancing disease resistance of crop plants in sustainable ways, including the potential for reduced pesticide usage. Certain GE applications involve transgenesis, in some cases creating a metabolic pathway novel to the GE crop. In other cases, only cisgenessis is employed. In yet other cases, engineered genetic changes can be so minimal as to be indistinguishable from natural mutations. Thus, GE crops vary substantially and should be evaluated for risks, benefits, and social considerations on a case-by-case basis. Deployment of GE traits should be with an eye towards long-term sustainability; several options are discussed. Selected risks and concerns of GE are also considered, along with genome editing, a technology that greatly expands the capacity of molecular biologists to make more precise and targeted genetic edits. While GE is merely a suite of tools to supplement other breeding techniques, if wisely used, certain GE tools and applications can contribute to sustainability goals. Keywords: biotechnology; GMO (genetically modified organism) 1. Introduction and Background Disease management practices can contribute to sustainability by protecting crop yields, maintaining and improving profitability for crop producers, reducing losses along the distribution chain, and reducing the negative environmental impacts of diseases and their management.
    [Show full text]
  • A Short History of DNA Technology 1865 - Gregor Mendel the Father of Genetics
    A Short History of DNA Technology 1865 - Gregor Mendel The Father of Genetics The Augustinian monastery in old Brno, Moravia 1865 - Gregor Mendel • Law of Segregation • Law of Independent Assortment • Law of Dominance 1865 1915 - T.H. Morgan Genetics of Drosophila • Short generation time • Easy to maintain • Only 4 pairs of chromosomes 1865 1915 - T.H. Morgan •Genes located on chromosomes •Sex-linked inheritance wild type mutant •Gene linkage 0 •Recombination long aristae short aristae •Genetic mapping gray black body 48.5 body (cross-over maps) 57.5 red eyes cinnabar eyes 67.0 normal wings vestigial wings 104.5 red eyes brown eyes 1865 1928 - Frederick Griffith “Rough” colonies “Smooth” colonies Transformation of Streptococcus pneumoniae Living Living Heat killed Heat killed S cells mixed S cells R cells S cells with living R cells capsule Living S cells in blood Bacterial sample from dead mouse Strain Injection Results 1865 Beadle & Tatum - 1941 One Gene - One Enzyme Hypothesis Neurospora crassa Ascus Ascospores placed X-rays Fruiting on complete body medium All grow Minimal + amino acids No growth Minimal Minimal + vitamins in mutants Fragments placed on minimal medium Minimal plus: Mutant deficient in enzyme that synthesizes arginine Cys Glu Arg Lys His 1865 Beadle & Tatum - 1941 Gene A Gene B Gene C Minimal Medium + Citruline + Arginine + Ornithine Wild type PrecursorEnz A OrnithineEnz B CitrulineEnz C Arginine Metabolic block Class I Precursor OrnithineEnz B CitrulineEnz C Arginine Mutants Class II Mutants PrecursorEnz A Ornithine
    [Show full text]
  • List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company
    List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Algeria Bayer Algerie S.P.A. Argentina Bayer S.A. Argentina Biagro S.A. Argentina Monsanto Argentina SRL Australia Bayer Australia Limited Australia Bayer CropScience Holdings Pty Ltd Australia Bayer CropScience Pty Limited Australia Cotton Growers Services Pty. Limited Australia Imaxeon Pty. Ltd. Australia Monsanto Australia Pty Ltd Bangladesh Bayer CropScience Ltd. Belgium Bayer Agriculture BVBA Belgium Bayer CropScience NV Belgium Bayer NV Bermuda MonSure Limited Bolivia Bayer Boliviana Ltda Bolivia Monsanto Bolivia S.A. Bosnia & Herzeg. Bayer d.o.o. Sarajevo Brazil Alkagro do Brasil Ltda Brazil Bayer S.A. Brazil D&PL Brasil Ltda Brazil Monsanto do Brasil Ltda. Brazil Rede Agro Fidelidade e Intermediacao S.A. Brazil Schering do Brasil Química e Farmacêutica Ltda. Brazil Stoneville Brasil Ltda. Bulgaria Bayer Bulgaria EOOD Burkina Faso Monsanto Burkina Faso SARL Chile Bayer Finance & Portfolio Management S.A. Chile Bayer Finance Ltda. Chile Bayer S.A. Chile Monsanto Chile, S.A. Costa Rica Bayer Business Services Costa Rica, SRL Costa Rica Bayer Medical S.R.L. Costa Rica Bayer S.A. Curacao Pianosa B.V. Germany Adverio Pharma GmbH - 1 - List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Germany AgrEvo Verwaltungsgesellschaft mbH Germany Alcafleu Management GmbH & Co. KG Germany BGI Deutschland GmbH Germany Bayer 04 Immobilien GmbH Germany Bayer 04 Leverkusen Fußball GmbH Germany Bayer 04 Leverkusen
    [Show full text]
  • DRAFT Landscape of COVID-19 Candidate Vaccines – 10 August 2020
    DRAFT landscape of COVID-19 candidate vaccines – 10 August 2020 28 candidate vaccines in clinical evaluation COVID-19 Vaccine Number of Route of Clinical Stage Vaccine platform Type of candidate vaccine Timing of doses developer/manufacturer doses Administration Phase 1 Phase 1/2 Phase 2 Phase 3 PACTR202006922165132 Non-Replicating University of Oxford/AstraZeneca ChAdOx1-S 1 IM 2020-001072-15 2020-001228-32 ISRCTN89951424 Viral Vector Interim Report NCT04383574 Sinovac Inactivated Inactivated 2 0, 14 days IM NCT04456595 NCT04352608 Wuhan Institute of Biological Inactivated Inactivated 2 0,14 or 0,21 days IM ChiCTR2000031809 ChiCTR2000034780 Products/Sinopharm Beijing Institute of Biological Inactivated Inactivated 2 0,14 or 0,21 days IM ChiCTR2000032459 ChiCTR2000034780 Products/Sinopharm NCT04283461 NCT04405076 NCT04470427 Moderna/NIAID RNA LNP-encapsulated mRNA 2 0, 28 days IM Interim Report 2020-001038-36 BioNTech/Fosun Pharma/Pfizer RNA 3 LNP-mRNAs 2 0, 28 days IM NCT04368728 ChiCTR2000034825 CanSino Biological Inc./Beijing Institute Non-Replicating ChiCTR2000030906 ChiCTR2000031781 Adenovirus Type 5 Vector 1 IM of Biotechnology Viral Vector Study Report Study Report Anhui Zhifei Longcom Adjuvanted recombinant protein 0,28 or 0,28,56 Protein Subunit 2 or 3 IM NCT04445194 NCT04466085 Biopharmaceutical/Institute of (RBD-Dimer) days DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).
    [Show full text]
  • Association for Consumer Research
    ASSOCIATION FOR CONSUMER RESEARCH Labovitz School of Business & Economics, University of Minnesota Duluth, 11 E. Superior Street, Suite 210, Duluth, MN 55802 Cyborg As Commodity: Exploring Conceptions of Self-Identity, Body and Citizenship Within the Context of Emerging Transplant Technologies Ai-Ling Lai, University of Leicester, UK This paper explores how advances in transplant technologies shape conceptions of self-identity, embodiment and citizenship. Drawing on the posthuman writing of Donna Haraway and through phenomenological interviews, I explore ambivalence towards the commoditization of the cyborg-body, suggesting that biotechnology may potentially lead to a dystopian posthuman consumer society. [to cite]: Ai-Ling Lai (2012) ,"Cyborg As Commodity: Exploring Conceptions of Self-Identity, Body and Citizenship Within the Context of Emerging Transplant Technologies ", in NA - Advances in Consumer Research Volume 40, eds. Zeynep Gürhan-Canli, Cele Otnes, and Rui (Juliet) Zhu, Duluth, MN : Association for Consumer Research, Pages: 386-394. [url]: http://www.acrwebsite.org/volumes/1011658/volumes/v40/NA-40 [copyright notice]: This work is copyrighted by The Association for Consumer Research. For permission to copy or use this work in whole or in part, please contact the Copyright Clearance Center at http://www.copyright.com/. Cyborg as Commodity: Exploring Conception of Self-Identity, Body and Citizenship within the Context of Emerging Transplant Technologies Ai-Ling Lai, University of Leicester, UK ABSTRACT technology (Thompson 2004). In doing so, I aim to contribute to This paper explores how advances in transplant technologies previous writings by Johnson and Roberts (1997) and Belk (1990). shape conceptions of self-identity, embodiment and citizenship. Most notably, these scholars observe how the marketing of organ Drawing on the posthuman writing of Donna Haraway and from transplantation has previously been predicated on the ‘mechanistic’ phenomenological interviews, I explore ambivalence towards the metaphor of the body (Belk 1990).
    [Show full text]
  • Barriers to Adoption of GM Crops
    Iowa State University Capstones, Theses and Creative Components Dissertations Fall 2021 Barriers to Adoption of GM Crops Madeline Esquivel Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents Part of the Agricultural Education Commons Recommended Citation Esquivel, Madeline, "Barriers to Adoption of GM Crops" (2021). Creative Components. 731. https://lib.dr.iastate.edu/creativecomponents/731 This Creative Component is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative Components by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Barriers to Adoption of GM Crops By Madeline M. Esquivel A Creative Component submitted to the Graduate Faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Plant Breeding Program of Study Committee: Walter Suza, Major Professor Thomas Lübberstedt Iowa State University Ames, Iowa 2021 1 Contents 1. Introduction ................................................................................................................................. 3 2. What is a Genetically Modified Organism?................................................................................ 9 2.1 The Development of Modern Varieties and Genetically Modified Crops .......................... 10 2.2 GM vs Traditional Breeding: How Are GM Crops Produced?
    [Show full text]
  • Whither Plant Genetic Engineering? Allow Crops to Tolerate Environmental Stress Such As Drought, Cold, Salt, Heat, Or flood
    PLANT TREK TO BOLDLY GO WHERE NO PLANT HAS GONE BEFORE On the Past, Present & Future of Plant Genetic Engineering by Richard G. Stout A HowPlantsWork.com eBook Copyright © 2013 by Richard G. Stout Version 1.0.1 PDF August, 2013 Table of Contents Preface Chapter 1: Where Do New Plants Come From? Chapter 2: How To Make A Transgenic Plant Chapter 3: Gene Guns, Terminators & Traitors Chapter 4: Farmaceuticals, Plantibodies & Edible Vaccines Chapter 5: Into The Wild Chapter 6: Are GM Plants Self-Replicating Inventions? Chapter 7: Plant Trek - The Next Generation Chapter 8: DIY Plant Genetic Engineering? Attributions About The Author Glossary about where plant biotechnology may be headed in the future, Preface including how plant biotechnology “hobbyists” may be getting into the act. Who is this book for? Please Note: This book is NOT a comprehensive textbook on plant genetic engineering and biotechnology. (If you’re looking This book is intended for people who may be curious about for such books, I’m sure you can find them at your local college plant genetic engineering, but who don’t want to read a long, bookstore or at an online bookseller.) Nor is this book meant to technical textbook on the subject. (There are provided, be a defense of genetically-engineered organisms (GMOs), however, ample links to books and articles - and also to online though I’m sure some readers will think so. Maybe here’s why. resources - for further reading.) If you’re looking for small “tastes” of information regarding various aspects of plant Since I was a graduate student in the 1970s at the University of genetic engineering, then this little book maybe just the Washington where some of the original work on transgenic informational “snack” that you’re looking for.
    [Show full text]
  • World Resources Institute the Monsanto Company
    World Resources Institute Sustainable Enterprise Program A program of the World Resources Institute The Monsanto Company: Quest for Sustainability (A) “Biotechnology represents a potentially sustainable For more than a decade, WRI's solution to the issue, not only of feeding people, but of providing Sustainable Enterprise Program (SEP) the economic growth that people are going to need to escape has harnessed the power of business to poverty…… [Biotechnology] poses the possibility of create profitable solutions to leapfrogging the industrial revolution and moving to a post- environment and development industrial society that is not only economically attractive, but challenges. BELL, a project of SEP, is also environmentally sustainable.i ” focused on working with managers and academics to make companies --Robert Shapiro, CEO, Monsanto Company more competitive by approaching social and environmental challenges as unmet market needs that provide Upon his promotion to CEO of chemical giant The business growth opportunities through Monsanto Company in 1995, Robert Shapiro became a vocal entrepreneurship, innovation, and champion of sustainable development and sought to redefine the organizational change. firm’s business strategy along principles of sustainability. Shapiro’s rhetoric was compelling. He captured analysts’ Permission to reprint this case is attention with the specter of mass hunger and environmental available at the BELL case store. degradation precipitated by rapid population growth and the Additional information on the Case
    [Show full text]
  • Agribusiness and Antitrust: the Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union
    The Global Business Law Review Volume 7 Issue 1 Article 9 7-1-2018 Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union Aleah Douglas Cleveland-Marshall College of Law Follow this and additional works at: https://engagedscholarship.csuohio.edu/gblr Part of the Antitrust and Trade Regulation Commons, and the Business Organizations Law Commons How does access to this work benefit ou?y Let us know! Recommended Citation Aleah Douglas, Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union, 7 Global Bus. L. Rev. 156 (2018) available at https://engagedscholarship.csuohio.edu/gblr/vol7/iss1/9 This Note is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in The Global Business Law Review by an authorized editor of EngagedScholarship@CSU. For more information, please contact [email protected]. AGRIBUSINESS AND ANTITRUST: THE BAYER-MONSANTO MERGER, ITS LEGALITY, AND ITS EFFECT ON THE UNITED STATES AND EUROPEAN UNION ALEAH DOUGLAS I. INTRODUCTION……………………………………………………………………... 157 II. BACKGROUND…………………………………………………………………….....158 A. A Review of the Bayer-Monsanto Merger………………………….…………... 158 B. United States Antitrust Laws…………………………………………………… 161 1. The Applicable Laws……………………………………………………. 161 2. Problems and Antitrust Violations……………………………………… 166 3. American Agribusiness…………………………………………………. 167 C. European Union Antitrust Laws……………………………………………….. 172 1. The European Union……………………………………………………. 172 2. The Applicable Laws………………………………….………………… 172 3. Problems and Antitrust Violations……………………….………....…... 174 4. European Union Agribusiness…………….…………………………….. 176 D. Illegality and Detriment …………………………………….…………………. 178 III. CONCLUSION……………………………………………………………………....... 180 ABSTRACT This note examines the current and historical antitrust laws of the United States and the European Union as they relate to the currently pending merger between Bayer and Monsanto.
    [Show full text]